Agent Orange study... double the CLL rate in A... - CLL Support

CLL Support

22,988 members39,473 posts

Agent Orange study... double the CLL rate in Australian and New Zealand veterans of Vietnam war

Cllcanada profile image
CllcanadaTop Poster CURE Hero
1 Reply

Vietnam veterans who served from 1962-1971 have double the rate of chronic lymphatic leukaemia compared to the general population according to a new study by the University of Otago’s Department of Preventive and Social Medicine.

The US Institute of Medicine, in their report ‘Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam’first classified chronic lymphatic leukaemia on their ‘sufficient evidence for cancer’ list in 2002, based on dioxin toxicity and studies of farm workers exposed to herbicides. The cohorts of Australian and New Zealand soldiers are the only group of Vietnam veterans to show an actual excess of the disease.

The results also show that although 407 veterans died over the study period the overall rate of death from all causes was 15% lower than the general population suggesting lower incidence of mortality and morbidity. Mortality from cancer was not significantly lower or higher however than the general population, and there was no decrease in ‘all cancer’ incidence.

“The pattern of lower overall mortality is known as the ‘healthy soldier effect’ which is related to the fact that this cohort would have been selected for its health and fitness,” says lead author Dr David McBride.

More:

otago.ac.nz/dsm/news/otago0...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
1 Reply
Cllcanada profile image
CllcanadaTop Poster CURE Hero

Full study is available here

bmjopen.bmj.com/content/3/9...

Not what you're looking for?

You may also like...

The Benefits of Exercise with CLL and COVID-19

With CLL being a relatively rare cancer, it is often hard to find studies specific to our cancer....

Canadian Study...treatment increases risk of secondary cancers in CLL

Treated CLL patients had a 1.7-fold increased risk of second cancers compared with untreated CLL...

Attention Those Taking Ibrutinib & BTK Inhibitors:Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

The publication examines the relationship between the use of ibrutinib and acalabrutinib with the...

Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis

The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation BTKis was based on...

Acalabrutinib Plus Venetoclax and Obinutuzumab Achieves High Bone Marrow uMRD Rate in Chronic Lymphocytic Leukemia - CLL

Great news from this long awaited first published phase 2 study reporting the efficacy of this AVO...